Evaluation of the expected survival time and course of treatment of patients after taking pirfenidone (Acere)

Pirfenidone (Pirfenidone, trade nameEsbriet) is an anti-fibrotic drug mainly used to treat patients with idiopathic pulmonary fibrosis (IPF). The drug slows down the fibrosis process of lung tissue by inhibiting pro-fibrotic factors such as transforming growth factor -β (TGF-β) and tumor necrosis factor -α (TNF-α), thereby delaying the progression of the disease. The main goal of taking pirfenidone is to improve patients' lung function, delay disease progression and improve quality of life. The impact on expected survival time needs to be evaluated based on the patient's specific condition.

In clinical studies, the overall expected survival time of IPF patients taking pirfenidone was prolonged. Multiple long-term follow-up studies have shown that pirfenidone can significantly reduce the risk of disease progression and delay the decline of lung function. Generally speaking, for early-stage or intermediate-stage patients, continued and standardized use of pirfenidone can prolong survival to a certain extent, but the specific time varies depending on the patient's age, baseline lung function, comorbid diseases, and treatment compliance. Patients should maintain close communication with their physician to obtain an individualized assessment of expectations.

Regarding treatment course evaluation, pirfenidone is usually a long-term oral treatment. It is generally recommended to take it three times a day with meals, and the maintenance dose reaches 2403 mg/ day or the tolerated dose adjusted by the doctor. During treatment, doctors will monitor efficacy through spirometry (such as FVC), imaging studies, and symptom assessment. If the patient's lung function is significantly stable or improved, it means that the treatment effect is better; if the condition continues to worsen, it is necessary to consider combining other anti-fibrosis strategies or adjusting the treatment plan.

Generally speaking, the treatment course design of pirfenidone emphasizes long-term standardized use and regular efficacy evaluation. While taking the medication, patients should regularly review lung function, liver function and kidney function, monitor drug tolerance, and pay attention to respiratory rehabilitation and physical strength management in daily life. Through scientific treatment course management and individualized evaluation, pirfenidone can prolong the survival period of IPF patients to a certain extent, improve the quality of life, and provide effective long-term support for disease management.

Reference materials:https://www.drugs.com/